Esaxerenone and Blood Pressure Control in Routine Clinical Practice

Abstract

Esaxerenone, a novel non-steroidal mineralocorticoid receptor antagonist, has emerged as a valuable therapeutic option for hypertension, particularly in patients with comorbidities such as chronic kidney disease and diabetes. This review synthesizes current evidence on esaxerenone’s efficacy, safety, and clinical applicability in routine practice, emphasizing its mechanisms, patient selection, and integration into guideline-directed management for optimal blood pressure control.

Introduction

Hypertension remains a leading modifiable risk factor for cardiovascular morbidity and mortality worldwide. Despite a broad armamentarium of antihypertensive agents, a significant proportion of patients fail to achieve optimal blood pressure (BP) targets, often due to resistant or secondary hypertension. Mineralocorticoid receptor antagonists (MRAs) have established efficacy in these settings, but steroidal agents like spironolactone and eplerenone are limited by adverse effects. Esaxerenone, a potent and selective non-steroidal MRA, offers a promising alternative with favorable efficacy and safety profiles. This article provides a comprehensive review of esaxerenone in routine clinical practice, integrating recent data, guideline updates, and practical recommendations for healthcare professionals.

Epidemiology / Disease Burden

Globally, hypertension affects over 1.3 billion adults, contributing to an estimated 10 million deaths annually. The prevalence of resistant hypertension—defined as uncontrolled BP despite three or more antihypertensive agents, including a diuretic—ranges from 10% to 20% among hypertensive populations. In addition, primary aldosteronism and mineralocorticoid excess are increasingly recognized contributors to difficult-to-control hypertension. Inadequate BP control is associated with increased risks of myocardial infarction, stroke, heart failure, and progression to end-stage renal disease, underscoring the need for more effective and better-tolerated therapeutic strategies such as esaxerenone.

Pathophysiology

The mineralocorticoid receptor (MR) plays a central role in sodium retention, potassium excretion, and arterial stiffness, mediated predominantly by aldosterone. Overactivation of MR in the kidneys and cardiovascular tissues leads to volume expansion, vascular inflammation, and fibrosis, all of which contribute to hypertension and target organ damage. Steroidal MRAs block aldosterone’s actions but interact with other steroid receptors, resulting in off-target effects. Esaxerenone is a highly selective non-steroidal MRA that inhibits MR activation without significant interactions with androgen or progesterone receptors, thereby reducing the risk of endocrine-related adverse events.

Risk Factors

Major risk factors for hypertension and mineralocorticoid-mediated BP elevation include advanced age, obesity, high dietary sodium intake, chronic kidney disease, diabetes mellitus, and genetic predisposition. Secondary hyperaldosteronism—often due to renal artery stenosis or heart failure—can further exacerbate BP elevation. Identification of patients at risk for resistant hypertension or primary aldosteronism is crucial for targeted therapy with MRAs such as esaxerenone.

Clinical Features

Patients with mineralocorticoid excess may present with hypertension that is often resistant to conventional therapy, hypokalemia, and evidence of target organ damage such as left ventricular hypertrophy, microalbuminuria, or retinopathy. Symptoms are generally nonspecific, including headaches, fatigue, and nocturia. In clinical practice, careful assessment of comorbidities and features suggestive of secondary hypertension guide the selection of advanced therapeutic agents.

Diagnosis

Diagnosis of hypertension is based on standardized BP measurements, often supplemented by ambulatory monitoring. For suspected mineralocorticoid-driven hypertension, laboratory assessment includes plasma aldosterone concentration, plasma renin activity, and serum potassium levels. Screening for primary aldosteronism is recommended in patients with resistant hypertension, hypokalemia, or adrenal incidentalomas. Imaging and confirmatory testing may be pursued as clinically indicated.

Treatment & Management

Initial hypertension management includes lifestyle modification and pharmacologic therapy—typically a combination of ACE inhibitors or ARBs, calcium channel blockers, and diuretics. For patients with resistant hypertension or confirmed mineralocorticoid excess, MRAs are indicated. Esaxerenone has demonstrated robust BP-lowering efficacy in clinical trials, with additional benefits on albuminuria reduction and target organ protection, particularly in patients with diabetes and chronic kidney disease. Recommended starting doses are titrated based on BP response, renal function, and potassium levels. Esaxerenone’s selectivity reduces the risk of gynecomastia and menstrual irregularities seen with steroidal MRAs.

Recent Advances / Emerging Therapies

Recent phase 3 trials and real-world studies have highlighted esaxerenone’s efficacy in lowering BP and improving renal outcomes. The ESAX-HTN and ESAX-DN studies demonstrated significant reductions in systolic and diastolic BP, as well as albuminuria, with a safety profile comparable to placebo or active comparators. Esaxerenone’s minimal interaction with other antihypertensive agents and low risk of hyperkalemia—particularly at lower doses—make it an attractive option for combination therapy. Ongoing research is exploring its role in heart failure and broader cardiovascular risk reduction.

Guideline Recommendations

Current hypertension guidelines recommend MRAs as add-on therapy for resistant hypertension, with esaxerenone recognized as a preferred agent due to its selectivity and tolerability. The Japanese Society of Hypertension and several expert consensus statements endorse esaxerenone for patients with hypertension complicated by diabetes, proteinuria, or chronic kidney disease. Dose titration and periodic monitoring of renal function and serum potassium are advised, especially in elderly patients or those with impaired renal function.

Conclusion

Esaxerenone represents a significant advancement in the management of hypertension, particularly in patients with resistant disease or comorbidities such as diabetes and chronic kidney disease. Its potent, selective inhibition of the mineralocorticoid receptor, favorable safety profile, and efficacy for both BP and renal protection position it as an important addition to the antihypertensive armamentarium. Ongoing studies will further elucidate its role in cardiovascular risk reduction and guide optimal integration into clinical practice.